Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Double-blind Treatment Period	STARTED	Fampridine-SR 10 mg b.i.d. Treatment	120
Double-blind Treatment Period	STARTED	Placebo Treatment	119
Double-blind Treatment Period	COMPLETED	Fampridine-SR 10 mg b.i.d. Treatment	113
Double-blind Treatment Period	COMPLETED	Placebo Treatment	114
Double-blind Treatment Period	NOT COMPLETED	Fampridine-SR 10 mg b.i.d. Treatment	7
Double-blind Treatment Period	NOT COMPLETED	Placebo Treatment	5
Post-study Follow-up	STARTED	Fampridine-SR 10 mg b.i.d. Treatment	113
Post-study Follow-up	STARTED	Placebo Treatment	114
Post-study Follow-up	COMPLETED	Fampridine-SR 10 mg b.i.d. Treatment	113
Post-study Follow-up	COMPLETED	Placebo Treatment	114
Post-study Follow-up	NOT COMPLETED	Fampridine-SR 10 mg b.i.d. Treatment	0
Post-study Follow-up	NOT COMPLETED	Placebo Treatment	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00483652/flow